Research Article

Value of bromocriptine in unexplained primary infertility: a double-blind controlled trial.

Br Med J 1979; 1 doi: http://dx.doi.org/10.1136/bmj.1.6170.1037 (Published 21 April 1979) Cite this as: Br Med J 1979;1:1037
  1. C S Wright,
  2. S J Steele,
  3. H S Jacobs

    Abstract

    In a double-blind controlled study, 47 women with unexplained primary infertility were allocated at random to treatment with either bromocriptine 2.5 mg twice daily (24 patients) or placebo (23). Both groups showed a fall in serum prolactin concentrations but the reduction was much greater in the bromocriptine-treated group. Neither group showed a change in serum oestrogen or progesterone concentrations. Bromocriptine significantly reduced the duration of the follicular phase of the menstrual cycle but had no effect on the luteal phase. Five women conceived during treatment with placebo and seven during treatment with bromocriptine, but analysis of the cumulative conception rates showed no significant difference between the groups. The women who conceived were significantly younger and had a significantly shorter history of infertility than the women who did not conceive, but subtracting the number of years of infertility from age eliminated this difference. The results show that bromocriptine in the dose and duration of administration used in the trial is of no value in unexplained primary infertility.